NO20076232L - Middel for regenerering og/eller besyttelse av nerver - Google Patents
Middel for regenerering og/eller besyttelse av nerverInfo
- Publication number
- NO20076232L NO20076232L NO20076232A NO20076232A NO20076232L NO 20076232 L NO20076232 L NO 20076232L NO 20076232 A NO20076232 A NO 20076232A NO 20076232 A NO20076232 A NO 20076232A NO 20076232 L NO20076232 L NO 20076232L
- Authority
- NO
- Norway
- Prior art keywords
- agonist
- effect
- regeneration
- disease
- nerves
- Prior art date
Links
- 210000005036 nerve Anatomy 0.000 title abstract 4
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000003019 Neurofibromatosis 1 Diseases 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000020469 nerve plexus disease Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 201000004931 neurofibromatosis Diseases 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 201000006380 plexopathy Diseases 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005164458 | 2005-06-03 | ||
| PCT/JP2006/311084 WO2006129788A1 (ja) | 2005-06-03 | 2006-06-02 | 神経再生および／または保護剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076232L true NO20076232L (no) | 2008-02-28 |
Family
ID=37481715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076232A NO20076232L (no) | 2005-06-03 | 2007-12-03 | Middel for regenerering og/eller besyttelse av nerver |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7863263B2 (pt) |
| EP (3) | EP2308510B1 (pt) |
| JP (1) | JP5040650B2 (pt) |
| KR (1) | KR101320810B1 (pt) |
| CN (1) | CN101237885B (pt) |
| AU (1) | AU2006253356B2 (pt) |
| BR (1) | BRPI0611079A2 (pt) |
| CA (1) | CA2610692C (pt) |
| ES (1) | ES2572755T3 (pt) |
| IL (2) | IL187840A (pt) |
| NO (1) | NO20076232L (pt) |
| NZ (1) | NZ563863A (pt) |
| RU (1) | RU2420316C2 (pt) |
| TW (1) | TWI404529B (pt) |
| WO (1) | WO2006129788A1 (pt) |
| ZA (1) | ZA200710414B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053707A1 (ja) | 2003-12-05 | 2005-06-16 | Ono Pharmaceutical Co., Ltd. | 馬尾神経組織血流増加剤 |
| JP5040650B2 (ja) * | 2005-06-03 | 2012-10-03 | 小野薬品工業株式会社 | 神経再生および／または保護剤 |
| WO2009148163A1 (ja) * | 2008-06-06 | 2009-12-10 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩剤 |
| TWI437987B (zh) | 2009-06-10 | 2014-05-21 | Ono Pharmaceutical Co | 具有膀胱排尿肌收縮及尿道括約肌鬆弛之作用的化合物 |
| SG10201503402XA (en) | 2010-01-27 | 2015-06-29 | Takeda Pharmaceutical | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent |
| DK2891651T3 (en) * | 2012-08-31 | 2017-06-06 | Ono Pharmaceutical Co | AMINAL SALT AND CRYSTALL THEREOF |
| PT2989098T (pt) * | 2013-03-15 | 2017-08-16 | Cayman Chemical Co Inc | Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4 |
| RU2535004C1 (ru) * | 2013-06-11 | 2014-12-10 | Николай Андреевич Козлов | Способ лечения грыж межпозвонковых дисков у собак |
| RU2535005C1 (ru) * | 2013-06-11 | 2014-12-10 | Николай Андреевич Козлов | Способ лечения грыж межпозвонковых дисков у собак |
| PL3733665T3 (pl) | 2017-12-25 | 2023-02-06 | Asahi Kasei Pharma Corporation | Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 |
| CA3108046A1 (en) * | 2018-07-31 | 2020-02-06 | Ono Pharmaceutical Co., Ltd. | Benzene derivative |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5525602B2 (pt) | 1973-05-10 | 1980-07-07 | ||
| US4087620A (en) | 1975-07-17 | 1978-05-02 | Ono Pharmaceutical Company | 15-Cycloalkyl-prostaglandin derivatives |
| JPS5231404A (en) | 1975-09-03 | 1977-03-09 | Toyo Tire & Rubber Co Ltd | Safe pneumatic tyre |
| JPS6036422B2 (ja) | 1979-01-29 | 1985-08-20 | 小野薬品工業株式会社 | プロスタグランジン類似化合物及びその製造方法 |
| JPS60197667A (ja) | 1984-03-19 | 1985-10-07 | Ono Pharmaceut Co Ltd | ６―ケト―プロスタグランジン類似化合物及びその製造方法 |
| JPS6152146A (ja) | 1984-08-20 | 1986-03-14 | Matsushita Electric Ind Co Ltd | 電動機 |
| JP3774907B2 (ja) | 1993-12-09 | 2006-05-17 | 小野薬品工業株式会社 | ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 |
| JPH07233145A (ja) | 1993-12-27 | 1995-09-05 | Taisho Pharmaceut Co Ltd | プロスタグランジンｅ１アミド類縁体 |
| US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| JPH08239356A (ja) | 1994-12-28 | 1996-09-17 | Ono Pharmaceut Co Ltd | ナフチルオキシ酢酸誘導体およびそれを有効成分として含有する医薬 |
| WO1997005091A1 (en) | 1995-07-26 | 1997-02-13 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives and drugs comprising the same as active ingredients |
| US5698598A (en) | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| JP3865842B2 (ja) | 1996-12-09 | 2007-01-10 | 大正製薬株式会社 | プロスタグランジンｅ１類縁体 |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| ATE237587T1 (de) | 1997-02-10 | 2003-05-15 | Ono Pharmaceutical Co | 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten |
| WO1998058911A2 (en) | 1997-06-23 | 1998-12-30 | Pfizer Inc. | Prostaglandin agonists |
| JPH1112249A (ja) | 1997-06-24 | 1999-01-19 | Taisho Pharmaceut Co Ltd | プロスタグランジンｅ類縁体 |
| JPH11130678A (ja) | 1997-08-27 | 1999-05-18 | Kaken Pharmaceut Co Ltd | 神経圧迫による神経障害改善剤 |
| US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| WO1999033794A1 (en) | 1997-12-25 | 1999-07-08 | Ono Pharmaceutical Co., Ltd. | φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| US6376533B1 (en) | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| JP4273407B2 (ja) * | 2001-07-23 | 2009-06-03 | 小野薬品工業株式会社 | Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤 |
| AU2003211574A1 (en) | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| DE10226390B4 (de) | 2002-06-13 | 2004-07-22 | Siemens Ag | Resistive Strombegrenzereinrichtung mit supraleitender Leiterbahn und nicht-supraleitendem Shunt |
| WO2004008411A1 (en) * | 2002-07-11 | 2004-01-22 | Nokia Corporation | Method and device for automatically changing a digital content on a mobile device according to sensor data |
| WO2004065365A1 (ja) | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
| WO2004089411A1 (ja) * | 2003-04-03 | 2004-10-21 | Ono Pharmaceutical Co., Ltd. | 脊柱管狭窄症治療剤 |
| EP1654219A2 (en) | 2003-07-18 | 2006-05-10 | Applied Research Systems ARS Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
| WO2005053707A1 (ja) | 2003-12-05 | 2005-06-16 | Ono Pharmaceutical Co., Ltd. | 馬尾神経組織血流増加剤 |
| WO2005061492A1 (ja) * | 2003-12-22 | 2005-07-07 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびそれらを有効成分とする薬剤 |
| US7858610B2 (en) * | 2004-08-10 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist |
| EP1806148A4 (en) | 2004-10-22 | 2009-12-02 | Ono Pharmaceutical Co | THERAPEUTIC PREPARATION FOR INHALATION |
| JP5040650B2 (ja) * | 2005-06-03 | 2012-10-03 | 小野薬品工業株式会社 | 神経再生および／または保護剤 |
-
2006
- 2006-06-02 JP JP2007519083A patent/JP5040650B2/ja not_active Expired - Fee Related
- 2006-06-02 NZ NZ563863A patent/NZ563863A/en not_active IP Right Cessation
- 2006-06-02 KR KR1020087000009A patent/KR101320810B1/ko not_active Expired - Fee Related
- 2006-06-02 CN CN2006800286854A patent/CN101237885B/zh not_active Expired - Fee Related
- 2006-06-02 EP EP10013710.8A patent/EP2308510B1/en not_active Expired - Lifetime
- 2006-06-02 EP EP12170571A patent/EP2494990A1/en not_active Withdrawn
- 2006-06-02 WO PCT/JP2006/311084 patent/WO2006129788A1/ja not_active Ceased
- 2006-06-02 EP EP06756919A patent/EP1886693A4/en not_active Withdrawn
- 2006-06-02 RU RU2007148992/15A patent/RU2420316C2/ru not_active IP Right Cessation
- 2006-06-02 CA CA2610692A patent/CA2610692C/en not_active Expired - Fee Related
- 2006-06-02 US US11/916,374 patent/US7863263B2/en not_active Expired - Fee Related
- 2006-06-02 ES ES10013710.8T patent/ES2572755T3/es not_active Expired - Lifetime
- 2006-06-02 AU AU2006253356A patent/AU2006253356B2/en not_active Ceased
- 2006-06-02 TW TW095119560A patent/TWI404529B/zh not_active IP Right Cessation
- 2006-06-02 BR BRPI0611079-7A patent/BRPI0611079A2/pt not_active IP Right Cessation
-
2007
- 2007-11-30 ZA ZA200710414A patent/ZA200710414B/xx unknown
- 2007-12-03 NO NO20076232A patent/NO20076232L/no not_active Application Discontinuation
- 2007-12-03 IL IL187840A patent/IL187840A/en not_active IP Right Cessation
-
2010
- 2010-08-01 IL IL207325A patent/IL207325A0/en unknown
- 2010-11-11 US US12/944,326 patent/US8404858B2/en not_active Expired - Fee Related
-
2013
- 2013-01-25 US US13/750,076 patent/US20130143934A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2610692A1 (en) | 2006-12-07 |
| RU2420316C2 (ru) | 2011-06-10 |
| CA2610692C (en) | 2014-11-25 |
| US20130143934A1 (en) | 2013-06-06 |
| IL187840A0 (en) | 2008-03-20 |
| RU2007148992A (ru) | 2009-06-27 |
| KR101320810B1 (ko) | 2013-10-21 |
| JP5040650B2 (ja) | 2012-10-03 |
| BRPI0611079A2 (pt) | 2010-08-03 |
| WO2006129788A1 (ja) | 2006-12-07 |
| JPWO2006129788A1 (ja) | 2009-01-08 |
| IL187840A (en) | 2011-12-29 |
| TWI404529B (zh) | 2013-08-11 |
| ZA200710414B (en) | 2008-11-26 |
| IL207325A0 (en) | 2011-08-01 |
| AU2006253356B2 (en) | 2011-12-01 |
| US8404858B2 (en) | 2013-03-26 |
| US7863263B2 (en) | 2011-01-04 |
| ES2572755T3 (es) | 2016-06-02 |
| AU2006253356A1 (en) | 2006-12-07 |
| US20110059920A1 (en) | 2011-03-10 |
| EP2308510A1 (en) | 2011-04-13 |
| KR20080016926A (ko) | 2008-02-22 |
| EP2308510B1 (en) | 2016-03-16 |
| EP1886693A4 (en) | 2010-03-03 |
| CN101237885A (zh) | 2008-08-06 |
| CN101237885B (zh) | 2011-01-19 |
| EP2494990A1 (en) | 2012-09-05 |
| TW200716103A (en) | 2007-05-01 |
| EP1886693A1 (en) | 2008-02-13 |
| US20090227644A1 (en) | 2009-09-10 |
| NZ563863A (en) | 2011-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020086726A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| WO2018106839A3 (en) | Systems and methods for treating neurological disorders | |
| WO2021252538A3 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| EP2698166A3 (en) | Complement inhibition for improved nerve regeneration | |
| WO2015165948A3 (en) | Compositions for the treatment of diabetic neuropathies | |
| NO20083240L (no) | Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia | |
| WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
| WO2015021434A3 (en) | Methods and apparatuses for skin treatment using non-thermal tissue ablation | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
| EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
| WO2007092190A3 (en) | Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity | |
| WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
| EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| NO20084374L (no) | Imidazoltiazolforbindelser for behandling av sykdom | |
| EP4397372A3 (en) | Methods of treating lennox-gastaut syndrome using fenfluramine | |
| TNSN08382A1 (en) | New compounds | |
| WO2014144606A3 (en) | Methods of treating muscular dystrophy | |
| BR112017009053A2 (pt) | dispositivo para inibição da atividade neural de um nervo do seio carotídeo ou corpo carotídeo, método para tratamento de uma condição, forma de onda elétrica neuromodulatória, e, uso de um dispositivo de neuromodulação para o tratamento de uma condição. | |
| BRPI0512161A (pt) | métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica | |
| WO2008033440A3 (en) | Treatment of hyperproliferative diseases with anthraquinones | |
| CO2018004684A2 (es) | Métodos para tratar la epilepsia | |
| WO2009067690A3 (en) | Methods for safe and effective treatment using oxazaphosphorine drugs | |
| NO20070914L (no) | Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander | |
| NO20073104L (no) | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |